Germany’s Medical Cannabis Market Has Grown at a Remarkable Pace

In 2025, medical cannabis Germany became one of the fastest-growing healthcare stories in Europe. Prescriptions surged by 3,300 per cent between March 2024 and December 2025. That figure comes from the Cannabis Barometer published by Bloomwell Group. The Frankfurt-based company operates Germany’s largest digital platform for cannabis prescriptions. For investors watching European healthcare, those numbers are hard to dismiss.

The catalyst was legislative. Germany’s Cannabis Act (CanG) removed cannabis from the country’s Narcotics Act. It also introduced the Medical Cannabis Act (MedCanG). That reform shifted prescriptions away from strict narcotic controls. Standard pharmaceutical processes replaced them. The administrative burden on physicians dropped considerably. Telemedicine platforms then began facilitating access at scale. Patients managing chronic conditions could reach a prescriber far more easily. That regulatory change is what pushed the Germany cannabis market ahead of its European peers so quickly.

Telemedicine Drove Prescription Volumes to Record Levels

Digital healthcare played a central role in this expansion. Bloomwell’s review drew on anonymised data from hundreds of thousands of patient prescriptions. These were processed through its app, e-prescriptions, and partner pharmacies between January 2024 and December 2025. The data shows a market that responded quickly once barriers were removed.

Many patients had previously been self-medicating. Telemedicine brought them into a regulated, supervised system. Prescriptions reached record highs in late 2025. Digital platforms cut waiting times significantly. They also offered a more accessible route to treatment than traditional in-person consultations.

The cost case is compelling too. Telemedicine and mail-order pharmacy combined could save health insurers an estimated 2.9 billion euros annually. That figure is compared with in-person care. Cannabis therapy was also linked to a reduction in sick leave worth around 2.7 billion euros per year. Importantly, there was no evidence of increased hospitalisation or higher daily usage after the reform.

“At a time when Germany’s healthcare system is overstretched, and health insurers are under financial pressure, this model should serve as a benchmark, not a target for rollback,” said Niklas Kouparanis, co-founder of Bloomwell Group.

What the Germany Cannabis Market Looks Like Today

The Germany cannabis market has matured quickly in product range and pricing. Fewer than 470 flower strains were available at the start of 2025. By the fourth quarter, that number had reached 720. Patient preferences have shifted too. Non-irradiated flowers now hold roughly 90 per cent of market share. Patients are clearly favouring natural, minimally processed products.

Prices have also fallen sharply. The average cost per gram dropped from €8.33 in January 2025 to €5.23 in December. That is a decline of more than three euros in under a year. Falling prices in a growing market generally point to healthy supply and competition.

Dr Julian Wichmann, co-founder of Bloomwell, explained what the data means clinically. “As physicians, we now have a breadth of real-world data showing that medical cannabis can be a safe and effective therapy for many conditions such as chronic pain, sleep disorders, inflammatory diseases or depression.” He added that shorter waiting times and strong health outcomes are now consistent features of the private market model.

Regulatory Uncertainty Remains the Central Risk

Not everything in this picture is without complication. Rapid growth has drawn political scrutiny. Germany’s Federal Ministry of Health drafted amendments to the framework in 2025. Health Minister Nina Warken pointed to a 400 per cent surge in cannabis imports. She cited this as evidence of potential misuse through telemedicine platforms.

In October 2025, the German Cabinet approved a draft amendment. It would ban new remote prescriptions and restrict mail-order cannabis sales. The draft was submitted to the EU’s Technical Regulations Information System. The first Bundestag reading took place on 18 December 2025. As of early 2026, the process is ongoing. Second and third readings are expected this spring.

Bloomwell’s co-founders disagree with the characterisation of the problem. Wichmann noted that concerns about abuse and addiction do not hold up against the data on medical cannabis Germany specifically. When compared with opioids and Z-drugs, both commonly prescribed for the same conditions, the dependency risks are considerably lower.

“If policymakers continue to stigmatise medical cannabis and restrict telemedicine and shipping pharmacies, they risk pushing vulnerable patients back to medications with more severe side effects as well as unsafe cannabis from unregulated sources,” Wichmann told the Investing News Network.

That is a point worth taking seriously. A regulated digital channel does not automatically signal misuse. It can equally mean patients choosing a supervised, legal route over unregulated alternatives. Restricting access too sharply tends to push demand into less visible, less safe places.

Investor Appetite for Medical Cannabis Germany Is Growing

Despite the regulatory headwinds, investment interest in medical cannabis Germany remains strong. North American investors have made notable acquisitions of key players, including Sanity Group and Remixian. That signals confidence in the market’s long-term foundations.

The structural shift in where value concentrates is worth noting. As prices fall and competition intensifies, traditional product-touching businesses face shrinking margins. Wholesalers and pharmacies are feeling this already. The companies better positioned are those with scalable digital infrastructure.

Kouparanis was direct about this. “Of course, as with all product-touching business models, such as wholesale and pharmacy, margins are decreasing.” That shift favours platforms capable of serving large patient volumes efficiently. Germany’s own fiscal pressures point in the same direction. Digitally delivered cannabis therapy costs considerably less than in-person models. That alignment with public health savings is not a small consideration for policymakers.

What This All Means for the Germany Cannabis Market

Medical cannabis Germany has established itself as a significant development in European healthcare. The data from Bloomwell’s Cannabis Barometer points to a market that is functioning well. It is more affordable, more accessible, and delivering measurable health outcomes.

The regulatory outlook is uncertain. That uncertainty introduces real risk for businesses invested in digital supply chains and telemedicine. How Germany’s parliament resolves the proposed amendments this spring will matter greatly for the sector.

The growth seen in the Germany cannabis market is not a bubble. It reflects patients gaining access to medically supervised treatment that was previously out of reach. That underlying demand does not vanish if regulations tighten. It simply moves elsewhere, and often into less safe territory.

For investors, the question is whether Germany’s policymakers follow the evidence or pull back from it.

Source: investingnews